|
|
|
| Correlations of serum CEA and CA19-9 levels with clinical staging of colorectal cancer |
| ZHANG Li-hua*, GU Si-meng, YE Ding, ZHANG Yu-ping, LI Zhen-jun, YING Xiao-jiang
|
| *Department of Anorectal Surgery of the Shaoxing People's Hospital,Shaoxing,Zhejiang 312000,China |
|
|
|
|
Abstract Objective To evaluate the value of serum CEA and CA19-9 concentration for clinical staging of colorectal cancer. Methods A total of 350 patients who underwent the surgical treatments for colorectal cancer between February 2015 to January 2017 were enrolled. The serum CEA and CA19-9 were detected by chemoluminescence method. Results The positive rate of CEA of patients in stageⅠto Ⅳ was 25.00%,36.69%,50.78% and 66.67%,respectively. The positive rate of CA19-9 of patients in stageⅠto Ⅳ was 2.94%,10.07%,17.97% and 53.33%,respectively. The positive rates of CEA and CA19-9 were gradually increased with the stage developing （P<0.05）. Results from multivariate logistic regression analysis showed that the positive levels of CEA and CA19-9 were risk factors in the TNM staging of colorectal cancer. The ORs and 95%CI were 1.790（1.163-2.755）and 3.476（1.790-6.749）,respectively. Conclusion The positive serum concentrations of CEA and CA19-9 showed significant associations with TNM staging. Preoperative serum concentrations of CEA and CA 19-9 could be auxiliary diagnostic indicators to assess the condition of colorectal cancer.
|
|
Received: 05 July 2017
Revised: 26 August 2017
Published: 04 January 2018
|
|
|
|
|
|
[1] ARNOLD M,SIERRA M S,LAVERSANNE M,et al. Global patterns and trends in colorectal cancer incidence and mortality[J]. Gut,2017,66（4）：683-691.
[2] 王世意,张彩,王彩飞. 定海区居民5年恶性肿瘤发病与死亡监测结果[J]. 浙江预防医学,2015,27（6）：588-590.
[3] 钱晓萍,潘琴琴,黄铮. 吴兴区2006—2009年恶性肿瘤发病趋势[J]. 浙江预防医学,2010,22（11）：16-17,19.
[4] 王振宁. 结直肠癌TNM分期的现状及发展方向[J]. 中华结直肠疾病电子杂志,2015,4（1）：5-7.
[5] 刘传,清水汪,王宁,等. 结直肠癌术前血清CEA、CA19-9表达水平与临床病理关系的研究[J]. 医学研究杂志,2012,41（3）：27-30.
[6] 乔峰妮,曹暂剑,杨向东. 结直肠癌血清癌胚抗原、糖类抗原19-9表达水平及其临床价值探讨[J]. 现代肿瘤医学,2015,23（9）：1255-1258.
[7] 张忠,金伟森. 结直肠癌患者术前血清癌胚抗原及糖类抗原19-9阳性与临床病理学特征的关系[J]. 武警医学,2017,28（1）：26-29.
[8] 高文龙,刘小宁,颜虹. Nemenyi法检验的SAS实现[J]. 中国卫生统计,2013,30（1）：119-120.
[9] 何小帆,江明凤,金赛燕. 多种肿瘤标志物联合检测的肺癌早期诊断价值[J]. 浙江预防医学,2014,26（7）：750-752,756.
[10] GOLD P,FREEEDMAN S O. Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and absorption techniques[J]. J Exp Med,1965,121（3）：439- 462.
[11] SCHMOLL H J,VAN C E,STEIN A,et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer：a personalized approach to clinical decision making[J]. Ann Oncol,2012,23（10）：2479-2516.
[12] 林评跃,李夏鲁. 血清CA19-9、CA724、CEA联合检测在结直肠癌患者TNM分期中的应用[J]. 大众科技,2015,17（6）：99-101.
[13] 钟武,张磊昌,钟世彪,等. 结直肠癌患者术前CEA、CA19-9浓度与临床病理特征及预后的关系[J]. 中国普通外科杂志,2015,24（4）：499-504.
[14] ZHONG W,YU Z,ZHAN J,et al. Association of serum levels of CEA,CA19-9,CA125,CYFRA21-1 and CA72-4 and disease characteristics in colorectal cancer[J]. Pathol Oncol Res,2015, 21（1）：83-95.
[15] 李晓红,杨丽,李婉澜,等. CA50及CA19-9在结肠癌患者中的临床应用价值[J]. 检验医学与临床,2015,12（21）：3248- 3250.
[16] 林鼎立. 肿瘤标志物CA19-9和CA242在胰腺癌中的诊断价值[J]. 中国当代医药,2015,22（26）：64-66.
[17] 孙洁,孟祥军. 血清CA199、CEA、CA125、CA724联合检测在胃癌诊断中的价值[J]. 中国实验诊断学,2014,18（12）：1936-1939.
[18] STIKSMA J,GROOTENDORST D C,VAN P W. CA19-9 as a marker in addition to CEA to monitor colorectal cancer[J]. Clin Colorectal Cancer,2014,13（4）：239-244.
[19] 陈洪兴,刘云安. 大肠癌肝转移患者外周血CEA、CA19-9水平变化及与预后的关系[J]. 社区医学杂志,2016,14（20）：35-36.
[20] 吕旭. CEA与CA19-9在结直肠癌中的表达及病理参数和预后关系探讨[J]. 中国农村卫生,2016,11（23）：59-60. |
|
|
|
